Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000229
• EU PAS number:
  EUPAS1000000229
• Study ID:
  1000000229
• Official title and acronym:
  Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Planned

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Planned: 27/02/2024

Actual: 27/02/2024

Study start date

Planned: 15/08/2024

Date of final study report

Planned: 01/02/2026

Study protocol

Initial protocol

C1071039 Non Interventional Protocol Study Real-world usage of ELREXFIO (ALTITUDE) V1.0 31 July 2024_Redacted.pdf

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable